NCT00192322 - Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children | Biotech Hunter

Enrollment

173

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

December 31, 2001

Study Completion Date

December 31, 2001

Conditions

Influenza

Interventions

BIOLOGICAL

CAIV-T 10^7

a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)

BIOLOGICAL

CAIVT 10^5

a single intranasal 0.2 mL dose of CAIV-T \<10\^5

BIOLOGICAL

Placebo

a single intranasal 0.2 mL dose of placebo

BIOLOGICAL

TIV

commercially available TIV injected intramuscularly

Trial Locations (2)

Division of Allergy Immunology and Infectious Disease, Pittsburgh

Suncoast Clinical Research, Inc., New Port Richey